Hollenberg Emma J, Lin Fay, Blaha Michael J, Budoff Matthew J, van den Hoogen Inge J, Gianni Umberto, Lu Yao, Bax A Maxim, van Rosendael Alexander R, Tantawy Sara W, Andreini Daniele, Cademartiri Filippo, Chinnaiyan Kavitha, Choi Jung Hyun, Conte Edoardo, de Araújo Gonçalves Pedro, Hadamitzky Martin, Maffei Erica, Pontone Gianluca, Shin Sanghoon, Kim Yong-Jin, Lee Byoung Kwon, Chun Eun Ju, Sung Ji Min, Gimelli Alessia, Lee Sang-Eun, Bax Jeroen J, Berman Daniel S, Sellers Stephanie L, Leipsic Jonathon A, Blankstein Ron, Narula Jagat, Chang Hyuk-Jae, Shaw Leslee J
Dalio Institute of Cardiovascular Imaging, New York-Presbyterian Hospital and Weill Cornell Medicine, New York, New York, USA; Emory University School of Medicine, Atlanta, Georgia, USA.
Dalio Institute of Cardiovascular Imaging, New York-Presbyterian Hospital and Weill Cornell Medicine, New York, New York, USA.
JACC Cardiovasc Imaging. 2022 Jun;15(6):1063-1074. doi: 10.1016/j.jcmg.2021.12.015. Epub 2022 Apr 13.
Among symptomatic patients, it remains unclear whether a coronary artery calcium (CAC) score alone is sufficient or misses a sizeable burden and progressive risk associated with obstructive and nonobstructive atherosclerotic plaque.
Among patients with low to high CAC scores, our aims were to quantify co-occurring obstructive and nonobstructive noncalcified plaque and serial progression of atherosclerotic plaque volume.
A total of 698 symptomatic patients with suspected coronary artery disease (CAD) underwent serial coronary computed tomographic angiography (CTA) performed 3.5 to 4.0 years apart. Atherosclerotic plaque was quantified, including by compositional subgroups. Obstructive CAD was defined as ≥50% stenosis. Multivariate linear regression models were used to measure atherosclerotic plaque progression by CAC scores. Cox proportional hazard models estimated CAD event risk (median of 10.7 years of follow-up).
Across baseline CAC scores from 0 to ≥400, total plaque volume ranged from 30.4 to 522.4 mm (P < 0.001) and the prevalence of obstructive CAD increased from 1.4% to 49.1% (P < 0.001). Of those with a 0 CAC score, 97.9% of total plaque was noncalcified. Among patients with baseline CAC <100, nonobstructive CAD was prevalent (40% and 89% in CAC scores of 0 and 1-99), with plaque largely being noncalcified. On the follow-up coronary CTA, volumetric plaque growth (P < 0.001) and the development of new or worsening stenosis (P < 0.001) occurred more among patients with baseline CAC ≥100. Progression varied compositionally by baseline CAC scores. Patients with no CAC had disproportionate growth in noncalcified plaque, and for every 1 mm increase in calcified plaque, there was a 5.5 mm increase in noncalcified plaque volume. By comparison, patients with CAC scores of ≥400 exhibited disproportionate growth in calcified plaque with a volumetric increase 15.7-fold that of noncalcified plaque. There was a graded increase in CAD event risk by the CAC with rates from 3.3% for no CAC to 21.9% for CAC ≥400 (P < 0.001).
CAC imperfectly characterizes atherosclerotic disease burden, but its subgroups exhibit pathogenic patterns of early to advanced disease progression and stratify long-term prognostic risk.
在有症状的患者中,单独的冠状动脉钙化(CAC)评分是否足以评估病情,或者是否会遗漏与阻塞性和非阻塞性动脉粥样硬化斑块相关的相当大的负担和进展风险,目前尚不清楚。
在CAC评分从低到高的患者中,我们旨在量化同时存在的阻塞性和非阻塞性非钙化斑块以及动脉粥样硬化斑块体积的连续进展情况。
共有698例疑似冠心病(CAD)的有症状患者接受了间隔3.5至4.0年的连续冠状动脉计算机断层扫描血管造影(CTA)检查。对动脉粥样硬化斑块进行量化,包括按成分亚组进行量化。阻塞性CAD定义为狭窄≥50%。使用多元线性回归模型通过CAC评分来测量动脉粥样硬化斑块的进展情况。Cox比例风险模型估计CAD事件风险(中位随访时间为10.7年)。
在基线CAC评分从0到≥400的范围内,总斑块体积从30.4立方毫米至522.4立方毫米不等(P<0.001),阻塞性CAD的患病率从1.4%增至49.1%(P<0.001)。CAC评分为0的患者中,97.9%的总斑块为非钙化斑块。在基线CAC<100的患者中,非阻塞性CAD较为普遍(CAC评分为0和1 - 99时分别为40%和89%),斑块大多为非钙化斑块。在随访的冠状动脉CTA检查中,基线CAC≥100的患者中,斑块体积增长(P<0.001)以及新的或恶化的狭窄病变出现(P<0.001)更为常见。进展情况因基线CAC评分的不同而在成分上有所差异。无CAC的患者非钙化斑块增长不成比例,钙化斑块每增加1立方毫米,非钙化斑块体积增加5.5立方毫米。相比之下,CAC评分≥400的患者钙化斑块增长不成比例,其体积增加是非钙化斑块的15.7倍。CAD事件风险随CAC评分呈分级增加,无CAC者发生率为3.3%,CAC≥400者为21.9%(P<0.001)。
CAC不能完美地描述动脉粥样硬化疾病负担,但其亚组呈现出从早期到晚期疾病进展的致病模式,并对长期预后风险进行分层。